Infinium Global Research Lung Cancer Therapeutics Market | Page 2

A latest report has been added to the wide database of Lung Cancer Therapeutics Market by Infinium Global Research. This report
studies the Lung Cancer Therapeutics Market by type of molecule (small molecules, biologics), disease type (NSCLC, SCLC) market
status and outlook of global and major regions, from manufacturers, and end industries. The objective of the study is to identify
market sizes of different segments & countries in recent years and to forecast the values for the next six years. Lung Cancer
Therapeutics Market provides opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive
landscape, latest trends, and product offerings of the major companies in the Lung Cancer Therapeutics Market. According to report
the global lung cancer therapeutics market is projected to grow at a CAGR of 10.5% over the forecast period of 2018-2024.
Segment Covered
The report on global lung cancer therapeutics market covers segments such as, type of molecule and disease type. On the basis of type
of molecule the global lung cancer therapeutics market is categorized into small molecules and biologics. On the basis of disease type
the global lung cancer therapeutics market is categorized into NSCLC and SCLC.
Geographic Coverage
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this
section the key trends and market size for each geography is provided over the period of 2016-2024. The countries covered in the
North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and
among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the
growth in the North America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential for the
market growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience a growth at a
CAGR of x.x% over the period of 2018-2024.
Companies Profiled:
The report provides profiles of the companies in the global lung cancer therapeutics market such as, Astellas Pharma, Pfizer, Amgen,
Celgene, AstraZeneca, F. Hofmann-La Roche, GlaxoSmithKline, Aetna, Agennix, Eli Lilly and Boston Biomedical.